Pfizer Inc. Q3 FY2026 Earnings Call Summary
PFE
NYSE
Healthcare
📅 2026-11-03
⏱ ~60 sec read
🟢 Bullish
⏱️ 60-Second Brief
Pfizer Inc. · Q3 FY2026
Stock Next Day
▲ 2.63%
$30.0 → $30.79
Revenue
$16.6B
EPS
$0.56
AI Sentiment
🟢 Bullish
Despite flat overall revenue due to expected declines in COV…
📌 Bottom Line:
Pfizer delivered a robust third quarter in 2026, showcasing strong growth in its non-COVID product portfolio and advancing a promising late-stage pipeline. The company's confident outlook led to an upward revision of its…
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Pfizer delivered a robust third quarter in 2026, showcasing strong growth in its non-COVID product portfolio and advancing a promising late-stage pipeline. The company's confident outlook led to an upward revision of its full-year 2026 financial guidance, signaling a successful strategic pivot towards sustainable long-term value creation.
📊 Key Financial Metrics
Revenue
$16.6B
EPS (Diluted)
$0.56
YoY Revenue Growth
0%
Gross Margin
76.8%
Net Income
$3.242B
AI Sentiment
🟢 Bullish
Despite flat overall revenue due to expected declines in COVID-19 products, the significant operational growth in non-COVID products and raised full-year guidance demonstrate a successful strategic pivot and strong pipeline execution, indicating positive future prospects.
✅ What Went Well
Exceptional Growth in Launched and Acquired Products: Revenues from recently launched and acquired products surged by an impressive 32% operationally, demonstrating the successful execution of Pfizer's strategy to diversify its portfolio and drive growth beyond COVID-19 products. Key contributors included Eliquis (up 25% operationally), Padcev (up 55% operationally), and the Vyndaqel family (up 12% operationally).
Robust Non-COVID Revenue Performance: Excluding the expected declines from Comirnaty and Paxlovid, Pfizer's core revenues grew a strong 7% operationally. This underlying growth across a broad range of products, such as Nurtec ODT/Vydura (up 33% operationally) and Lorbrena (up 43% operationally), highlights the resilience and strength of the company's established and emerging franchises.
Optimistic Full-Year Guidance Revision: Management raised its full-year 2026 revenue guidance by $1.5 billion at the midpoint, now projecting $62.0 to $64.0 billion, and also increased and narrowed its Adjusted diluted EPS guidance to $2.95 to $3.05. This upward revision signals strong confidence in the company's operational momentum and future financial performance, despite a challenging market environment.
Advancing a Deep and Diverse Pipeline: Pfizer reported significant progress in its late-stage pipeline, with eight new pivotal study starts, one pivotal readout, and two regulatory decisions. This includes positive Phase 3 results for Elrexfio in multiple myeloma and Litfulo in vitiligo, as well as expanded FDA approvals for Talzenna in prostate cancer and Tukysa in breast cancer, underscoring the company's commitment to bringing innovative medicines to patients.
⚠️ Concerns & Risks
Overall Revenue Flatness Driven by COVID-19 Product Declines: While non-COVID products showed strong growth, total revenues remained relatively flat year-over-year operationally at $16.6 billion (0% growth). This was primarily due to significant operational decreases in Paxlovid (down 63% or $771 million) and Comirnaty (down 29% or $339 million), reflecting the anticipated reduction in demand for COVID-19 related products.
Decline in Established Product Categories: The Prevnar family of vaccines experienced a 10% operational decrease in revenues, driven by lower vaccination rates in adult and pediatric indications in the U.S. and market share erosion. This highlights the ongoing challenge of managing mature product portfolios against competitive pressures and changing market dynamics.
Reported Net Income and EPS Decline: Reported Net Income decreased 8% to $3.242 billion, and Reported Diluted EPS fell 9% to $0.56 compared to the prior-year quarter. This decline was influenced by factors such as higher R&D expenses (up 18% operationally) and the non-recurrence of certain favorable tax adjustments from the prior year, impacting GAAP profitability.
Future Generic and Biosimilar Competition: Pfizer anticipates an unfavorable revenue impact of approximately $1.1 billion in 2026 due to recent and expected generic and biosimilar competition for certain products. This ongoing patent cliff exposure necessitates continuous innovation and successful new product launches to offset potential revenue erosion.
🔮 CEO / Management Guidance
Pfizer raised its full-year 2026 revenue guidance by $1.5 billion at the midpoint, now projecting a range of $62.0 to $64.0 billion, up from $60.5 to $62.5 billion previously. The company also raised and narrowed its full-year 2026 Adjusted diluted EPS guidance to a range of $2.95 to $3.05, reflecting strong year-to-date performance and confidence in its business. This updated guidance includes a one-time $650 million Acquired In-Process R&D charge related to an in-licensing and collaboration agreement.
💬 Key Quote
Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. — Cecile Guegan, CFO and EVP
📅 Quarter-over-Quarter Comparison
Comparing Q3 FY2026
vs Q2 FY2026
All quarters →
Revenue
$15.0B
→
$16.6B
EPS
$0.77
→
$0.56
Gross Margin
75.7%
→
76.8%
Net Income
-$248M
→
$3.242B
YoY Growth
1%
→
0%
Sentiment
🟡 Neutral
→
🟢 Bullish
🏢 About Pfizer Inc.
Pfizer Inc. (PFE) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Pharmaceuticals
Earnings
Guidance
Drug Development
Biotechnology
📁 More from Pfizer Inc.
View all earnings summaries for Pfizer Inc. →